TNF inhibitor therapy for rheumatoid arthritis
- 29 November 2012
- journal article
- Published by Spandidos Publications in Biomedical Reports
- Vol. 1 (2), 177-184
- https://doi.org/10.3892/br.2012.42
Abstract
Immunotherapy has markedly improved treatment outcomes in rheumatoid arthritis (RA). Tumor necrosis factor (TNF)‑α antagonists, such as infliximab (IFX), etanercept (ETN), adalimumab (ADA), golimumab (GOLI) and certolizumab pegol (CZP) have been widely used for the treatment of RA. IFX provides significant, clinically relevant improvement in physical function and the quality of life, inhibits progressive joint damage and sustains improvement in the signs and symptoms of patients with RA. ETN is effective and safe for patients with RA. Combination therapy with ETN plus methotrexate (MTX) reduces disease activity, decreases total joint score progression, slows the pace of joint destruction and improves function more effectively compared to any of the monotherapies. ADA with or without MTX also relieves the signs and symptoms of RA. CZP and GOLI expand the therapeutic schedule for patients with RA. The TNF‑α inhibitors have similar efficacy, but distinct clinical pharmacokinetic and ‑dynamic properties. The common adverse events of these TNF‑α antagonists include adverse reactions, infections and injection‑site reaction. Additionally, these adverse events are mostly mild or moderate and their incidence is low. Certain patients exhibit a lack of response to anti‑TNF‑α therapies. Some patients may discontinue the initial drug and switch to a second anti‑TNF‑α agent. The shortage of clinical response to one agent may not predict deficiency of response to another. This review mainly addresses the latest developments of these biological agents in the treatment of RA.Keywords
This publication has 69 references indexed in Scilit:
- Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)Modern Rheumatology, 2011
- Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyRheumatology International, 2011
- Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING studyModern Rheumatology, 2009
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnnals Of The Rheumatic Diseases, 2008
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnnals Of The Rheumatic Diseases, 2008
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyAnnals Of The Rheumatic Diseases, 2008
- Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexateAnnals Of The Rheumatic Diseases, 2008
- The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor expression in the synoviumAnnals Of The Rheumatic Diseases, 2008
- Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drugRheumatology, 2008
- Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyAnnals Of The Rheumatic Diseases, 2007